Prelude Therapeutics Files 8-K Report
Ticker: PRLD · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1678660
Sentiment: neutral
Topics: 8-K, regulatory-filing, SEC
TL;DR
Prelude Therapeutics filed a routine 8-K, no major news yet.
AI Summary
On September 9, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it confirms the company's reporting status.
Why It Matters
This filing indicates Prelude Therapeutics is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a standard regulatory disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-39527 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1384762 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- September 9, 2024 (date) — Date of earliest event reported
- Delaware (location) — State of incorporation
- 175 Innovation Boulevard (address) — Principal executive offices
- Wilmington (location) — City of principal executive offices
- 19805 (zip_code) — ZIP code of principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not detail the specific information disclosed under Regulation FD, only that it is an item of information for the report.
What are the key exhibits included in this 8-K filing?
The excerpt lists 'Financial Statements and Exhibits' as an item of information, but does not specify which exhibits are included.
Has Prelude Therapeutics Incorporated undergone any name changes recently?
The filing indicates a former name change on June 30, 2016, but does not suggest any recent name changes.
What is the primary business of Prelude Therapeutics Incorporated?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Prelude Therapeutics Incorporated?
The fiscal year end for Prelude Therapeutics Incorporated is December 31 (1231).
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-09 09:02:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
Filing Documents
- prld-20240909.htm (8-K) — 48KB
- prld-ex99_1.htm (EX-99.1) — 25KB
- 0000950170-24-104575.txt ( ) — 222KB
- prld-20240909.xsd (EX-101.SCH) — 49KB
- prld-20240909_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 9, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing the publication of an abstract regarding PRT3789, a novel, highly-selective SMARCA2 degrader, at the European Society of Medical Oncology (ESMO) Congress 2024 on September 9, 2024. The Company plans on giving an oral presentation on the abstract on September 13, 2024 at 10:00 a.m. EST and will host an investor webcast on September 13, 2024 at 12:00 p.m. EST. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished, but shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: September 9, 2024 By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer